Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjcard.2019.08.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Re-thinking the link between exposure to mercury and blood pressure.
Arch Toxicol
January 2025
Chemical and Environmental Toxicology Program, Department of Biology, University of Ottawa, 30 Marie Curie, Ottawa, ON, K1N 6N5, Canada.
Hypertension or high blood pressure (BP) is a prevalent and manageable chronic condition which is a significant contributor to the total global disease burden. Environmental chemicals, including mercury (Hg), may contribute to hypertension onset and development. Hg is a global health concern, listed by the World Health Organization (WHO) as a top ten chemical of public health concern.
View Article and Find Full Text PDFZilebesiran and Hypertension: A Systematic Review and Meta-analysis.
J Saudi Heart Assoc
December 2024
College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Objectives: Zilebesiran is an investigational RNA interference therapeutic designed to lower blood pressure by targeting the hepatic production of angiotensinogen, the most upstream precursor of the renin-angiotensin-aldosterone system. This approach aims to offer long-lasting blood pressure control with potentially fewer doses compared to traditional antihypertensive medications. The objective of this systematic review and meta-analysis was to assess the antihypertensive efficacy of zilebesiran in patients with hypertension.
View Article and Find Full Text PDFAzelnidipine and its role in decreasing urinary albumin creatinine ratio in people with type 2 diabetes and hypertension: a systematic review and meta-analysis.
J Diabetes Metab Disord
June 2025
Department of Medicine, Gandhi Ward, King George's Medical University, Lucknow, India.
Purpose: Type 2 diabetes mellitus and hypertension frequently coexist, increasing the risk of cardiovascular and renal complications. Urinary Albumin Creatinine Ratio (UACR) serves as a crucial predictor of these outcomes. While renin-angiotensin system inhibitors are often initial therapy, evidence suggests a potential role for Azelnidipine, a non-dihydropyridine calcium channel blocker, in reducing UACR, especially in cases of persistent proteinuria despite optimal therapy.
View Article and Find Full Text PDFCorrigendum to "Continuation versus discontinuation of renin-angiotensin aldosterone system inhibitors before non-cardiac surgery: A systematic review and meta-analysis".
J Clin Anesth
January 2025
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA; Department of Internal Medicine, AdventHealth, Sebring, FL, USA. Electronic address:
The Impact of Concomitant Medications on the Overall Survival of Patients Treated with Systemic Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
Clin Genitourin Cancer
December 2024
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Semmelweis University, Budapest, Hungary; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia; Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Research Center for Evidence Medicine, Urology Department Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address:
Article Synopsis
- Immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI) are standard treatments for advanced renal cell carcinoma, but the impact of other medications taken alongside these treatments is uncertain.
- A review of 22 studies involving over 16,000 patients found that certain concomitant medications like proton pump inhibitors and antibiotics negatively affect overall survival when taken with ICIs, while statins, renin-angiotensin system inhibitors, and beta-blockers improve survival when combined with TKIs.
- Clinicians should evaluate patients' baseline medications before starting systemic therapy for metastatic RCC, as some drugs can either reduce or enhance the effectiveness of cancer treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!